The MENA Fabry Disease Treatment Market was valued at USD 167.76 million in 2024 and is projected to grow at a CAGR of 5.8% during 2025–2034, reaching approximately USD 295.32 million by 2034. Fabry disease is a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, leading to the accumulation of globotriaosylceramide (Gb3) in cells. This condition...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek
Arabic